New Recommendations Developed for Breast Cancer Screening
Guideline based on individual breast cancer risk profile, with specific screening strategies
Breast Cancer
Kadcyla Approved as Adjuvant Treatment for HER2-Positive Early Breast Cancer
The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. The approval was supported by data from the phase 3 KATHERINE study which evaluated the safety and efficacy of Kadcyla vs…
Guidance Statements Issued for Breast Cancer Screening
Clinicians should discuss mammography with patients aged 40 to 49, discontinue screening for those ≥75
Ready-to-Infuse Chemotherapy Product Infugem Now Available
Sun Pharma announced the launch of Infugem (gemcitabine in sodium chloride injection) 10mg/mL for intravenous (IV) use in a ready-to-administer (RTA) bag.
Ibrance Approved to Treat Male Patients With Breast Cancer
The FDA has expanded the indication of Ibrance (palbociclib; Pfizer) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients, in combination with an aromatase inhibitor or fulvestrant.
FDA Panel: Too Early to Ban Breast Implant Linked With Cancer
There is growing evidence that certain breast implants can trigger a rare form of lymphoma that grows in the scar tissue surrounding the breasts.
Emotionally Responsive Virtual Coach Helps Address Patient Concerns in New Simulation
Kognito, a health simulation company, is applying its simulation technology to patient education, to address a gap in patient knowledge.
Acupressure Reduces Lasting Symptoms in Breast Cancer Survivors
Tied to improvements in pain, anxiety, depression among breast cancer survivors with fatigue
Trazimera, a Biosimilar to Herceptin, Gets FDA Approval
The FDA has approved Trazimera (trastuzumab-qyyp; Pfizer), a biosimilar to Herceptin (trastuzumab; Genentech).
First Cancer Immunotherapy Regimen Approved for Breast Cancer Treatment
The Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab; Genentech) in combination with Abraxane.
